Last reviewed · How we verify
Inhaled budesonide
Inhaled budesonide, marketed by Instituto Nacional de Cancerologia de Mexico, holds a position in the respiratory therapy segment with a key composition patent expiring in 2028. The drug's key strength lies in its well-established mechanism and market presence, providing a reliable treatment option for patients. The primary risk is the upcoming patent expiry, which could lead to increased competition from generic alternatives.
At a glance
| Generic name | Inhaled budesonide |
|---|---|
| Also known as | Numark, Budesonide Powder for Inhalation, PULMICORT® NEBUAMP® |
| Sponsor | Instituto Nacional de Cancerologia de Mexico |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Effects of Different Drugs for Glottic Atomization on Postoperative Sore Throat After Thyroid Surgery (PHASE4)
- Study of Lunsekimig (SAR443765) Compared With Placebo in Adults With High-risk Asthma (PHASE2)
- Pooled Analysis of Single-arm Studies of Budesonide/Glycopyrronium/Formoterol (BGF) in Routine Care Setting
- Inhaled Budesonide for REcurrence Prevention and Adjuvant THerapy in Checkpoint Inhibitor Pneumonitis (PHASE2)
- A Study to Investigate the Effect of Budesonide/Glycopyrronium/Formoterol Fumarate Metered Dose Inhaler (BGF MDI) Compared With Placebo MDI on Heart and Lung Function in Participants With Chronic Obstructive Pulmonary Disease (COPD) and Hyperinflation (PHASE4)
- Post-marketing Phase 4 Safety & Tolerability Study of Breztri aerosphereTM in Indian Patients With Chronic Obstructive Pulmonary Disease (PHASE4)
- Ventilation and Perfusion in Asthmatics (PHASE4)
- A Study to Investigate How Budesonide and Formoterol Move Through the Body (Pharmacokinetics) When Delivered With Different Devices in Participants Aged 4 to Less Than 12 Years Old With Asthma (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Inhaled budesonide CI brief — competitive landscape report
- Inhaled budesonide updates RSS · CI watch RSS
- Instituto Nacional de Cancerologia de Mexico portfolio CI